Gain Therapeutics Inc [GANX] stock is trading at $1.78, up 9.88%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GANX shares have gain 20.27% over the last week, with a monthly amount glided 31.85%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on April 12, 2021, and set its price target to $30. On April 12, 2021, BTIG Research initiated with a Buy rating and assigned a price target of $30 on the stock.
Gain Therapeutics Inc [GANX] stock has fluctuated between $0.89 and $5.33 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Gain Therapeutics Inc [NASDAQ: GANX] shares were valued at $1.78 at the most recent close of the market. An investor can expect a potential return of 293.26% based on the average GANX price forecast.
Analyzing the GANX fundamentals
Gross Profit Margin for this corporation currently stands at -0.32% with Operating Profit Margin at -337.23%, Pretax Profit Margin comes in at -332.45%, and Net Profit Margin reading is -333.33%. To continue investigating profitability, this company’s Return on Assets is posted at -1.13, Equity is -2.14 and Total Capital is -1.72. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6579 points at the first support level, and at 1.5359 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8760, and for the 2nd resistance point, it is at 1.9721.
Ratios To Look Out For
For context, Gain Therapeutics Inc’s Current Ratio is 2.84. In addition, the Quick Ratio stands at 2.84 and the Cash Ratio stands at 2.6.
Transactions by insiders
Recent insider trading involved Mack Gene, CFO and Interim CEO, that happened on Aug 09 ’24 when 14400.0 shares were purchased. Executive Chairman, Islam Khalid completed a deal on Aug 09 ’24 to buy 50000.0 shares. Meanwhile, Director RICHMAN ERIC I bought 17000.0 shares on Jul 01 ’24.
